At a glance: KLOW combines four research peptides (GHK-Cu, KPV, BPC-157 and TB-500) in one vial, marketed for healing, skin and inflammation. The blend has never been tested in any published study. Each ingredient has mostly animal or lab data, none is FDA-approved for injection, and injectable blends like KLOW are not eligible for pharmacy compounding.
What is KLOW?
KLOW is a pre-mixed blend of four separate peptides, sold mainly by med spas, clinics and research-chemical vendors. The name comes from its ingredients: it is the same as the "GLOW" blend (GHK-Cu, BPC-157 and TB-500) with KPV added. There is no standard formulation: amounts, ratios and purity vary from seller to seller.
| Ingredient | What it is | Role it is marketed for |
|---|---|---|
| GHK-Cu | A naturally occurring copper-binding tripeptide (glycine-histidine-lysine) whose levels fall with age | Collagen, skin quality, wound repair |
| KPV | A three-amino-acid fragment (lysine-proline-valine) of the hormone alpha-MSH | Calming inflammation, especially in the gut and skin |
| BPC-157 | A 15-amino-acid peptide derived from a protective protein in gastric juice | Tendon, muscle and gut repair |
| TB-500 | A short synthetic fragment of thymosin beta-4, a cell-migration protein | Directing cells to injured tissue, limiting scarring |
How is KLOW supposed to work?
The idea is that four peptides with different proposed actions cover more ground together: GHK-Cu supports collagen and remodeling, KPV dampens inflammation, BPC-157 supports blood supply and tissue repair, and TB-500 helps cells migrate to damaged areas. Sellers describe specific pairings, such as BPC-157 with KPV for the gut or TB-500 with GHK-Cu for scarring.
These combinations are theories built from separate studies of each ingredient, mostly in cells and animals. No study has tested whether the four work together, interfere with each other, or are stable when mixed in one vial.
What the research shows so far
- GHK-Cu has the longest research record of the four, dating to the 1970s. It raised collagen in rat wound studies and sped healing of ischemic wounds in rats. Human data are limited to topical skin products and are thin; a 2025 review called clinical studies "surprisingly scarce." No trial of injected GHK-Cu has been published.
- KPV reduced intestinal inflammation in mouse colitis models, where it was absorbed by gut cells through a peptide transporter. There are no human studies.
- BPC-157 has many rat studies on tendon, muscle and gut healing. A 2025 systematic review found 36 studies, 35 of them preclinical; the only clinical report was an uncontrolled chart review of 16 knee-injection patients.
- TB-500 has no human studies at all, according to FDA's 2026 review. In the one lab wound test FDA found, it did not significantly speed wound closure.
- Combinations: a 2026 rat Achilles-tendon study found that BPC-157 and TB-500 together added no benefit over either alone. No study of GLOW or KLOW exists.
Why it gets attention
- All-in-one appeal: one vial promising recovery, skin and anti-inflammatory benefits
- Med spa and wellness marketing, often with results timelines that are not based on studies
- Popularity of its ingredients, especially BPC-157 and GHK-Cu
- Regulatory news in 2026, which put several of its ingredients in the headlines
How it is given
KLOW is sold as a powder to be mixed and injected under the skin. Because the four peptides are fixed in one vial, the amount of each changes together, and there is no way to adjust one ingredient. There is no established human dose for the blend or for any ingredient by injection, and this page does not provide dosing guidance.
What about side effects?
The blend's safety has never been studied. Risks reported or theorized for its ingredients include injection-site redness and swelling, nausea, fatigue and lightheadedness. Combining four unstudied peptides also combines their unknowns.
- Growth and blood-vessel signaling: BPC-157, TB-500 and GHK-Cu are linked to tissue-growth pathways, a concern for anyone with a history of cancer.
- Copper exposure: GHK-Cu delivers copper, which matters for people with copper-metabolism disorders such as Wilson disease.
- Immune reactions and impurities: FDA has flagged immunogenicity and peptide impurities as concerns for injectable peptides; mixing several in one vial adds stability and compatibility questions.
- Infection: products from unregulated labs may not be sterile.
- Pregnancy and breastfeeding: safety not established.
Regulatory status
- None of the four ingredients is FDA-approved as an injectable drug.
- In April 2026 FDA removed BPC-157, TB-500, KPV and injectable GHK-Cu, among other peptides, from its "Category 2" list of substances raising significant safety concerns. That was not a safety finding and did not make them eligible for compounding.
- In July 2026 an FDA advisory committee voted 8 to 6, with 1 abstention, to recommend each of BPC-157, TB-500 and KPV for the compounding list, against the advice of FDA's own reviewers. The vote is non-binding and rulemaking is pending.
- Injectable GHK-Cu is scheduled for a separate advisory review expected by February 2027. Topical GHK-Cu is widely used in cosmetics.
- Injectable blends like KLOW are not eligible for 503A compounding. Products sold as KLOW are research chemicals labeled not for human use, with no assurance of purity, potency or sterility.
- BPC-157 and TB-500 are on the World Anti-Doping Agency's prohibited list.
KLOW vs GLOW
| KLOW | GLOW | |
|---|---|---|
| Ingredients | GHK-Cu, KPV, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500 |
| Marketed focus | Recovery plus inflammation (gut, skin) | Recovery and skin |
| Studies of the blend | None | None |
| Compounding eligibility (injectable) | Not eligible | Not eligible |
The bottom line
KLOW bundles four peptides that each have interesting early research, mostly in animals and lab dishes, into a product that has never been tested as a combination. Claims about faster healing, better skin, more energy or results within weeks are not backed by studies of the blend. With unknown safety, no standard formulation and no regulatory oversight, anyone interested in recovery, skin or inflammation treatment should talk with a licensed clinician about evidence-based options.
Frequently asked questions
What is KLOW (blend)?
A combination of four separate peptides sold together in one vial. Each one has its own page on this site.
How is KLOW (blend) taken?
No established route.
Is KLOW (blend) FDA approved?
Not approved.
That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.
What has research shown about KLOW (blend)?
- No studies have tested this combination. Research on each peptide is summarized on its own page.
What side effects have been reported?
- Unknown for the combination
Serious or less common risks are listed in the Side Effects section above.
What is still unknown about its safety?
Most of it. KLOW (blend) has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.
References
- It's A Secret Med Spa: Everything you should know about KLOW (2026). View source
- Superpower: GLOW peptide blend and how KLOW differs (research summary with primary citations). View source
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. View source
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018. View source
- FDA: evaluation of TB-500 and TB-500 acetate for the 503A bulks list (2026). View source
- Goodwin: FDA signals potentially evolving stance toward compounding of certain peptides (May 2026). View source
- Orrick: FDA peptide compounding vote, what to watch at the July PCAC meeting (2026). View source
- AJMC: FDA panel backs 6 peptides for compounding (July 2026). View source